| 1 |
Kestenbaum B. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment[J]. Semin Dial,2007,20(4):286-294.
|
| 2 |
Reshkin SJ, Forgo J, Biber J, et al. Functional asymmetry of phosphate transport and its regulation in opossum kidney cells:phosphate “adaptation” [J]. Pflugers Arch, 1991, 419(3-4):256-262.
|
| 3 |
Murer H, Hernando N, Forster L, et al. Molecular mechanisms in proximal tubular and small intestinal phosphate reabsorption(plenary lecture) [J]. Mol Membr Biol,2001,18(1):3-11.
|
| 4 |
Barac-Nieto M,Alfred M,Spitzer A. Phosphate depletion in opossum kidney cells: apical but not basolateral or transepithelial adaptions of Pi transport [J]. Exp Nephrol,2001,9(4):258-264.
|
| 5 |
Bacic D, Lehir M, Biber J, et al. The renal Na + /phosphate cotransporter NaPi-IIa is internalized via the receptor-mediated endocytic route in response to parathyroid hormone [J]. Kidney Int,2006,69(3):495-503.
|
| 6 |
Saito H, Kusano K, Kinosaki M, et al. Human fibroblast growth factor-23 mutants suppress Na +-dependent phosphate co-transport activity and 1alpha,25-dihydroxyvitamin D3 production [J]. J Biol Chem,2003,278(4):2206-2211.
|
| 7 |
Gutierrez O, Isakova T, Rhee E, et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease [J]. J Am Soc Nephrol, 2005, 16(7):2205-2215.
|
| 8 |
Shigematsu T, Kazama JJ,Yamashita T, et al. Possible involvement of circulating fibroblast growth factor 23 in the development of secondary hyperparathyroidism associated with renal insufficiency[J]. Am J Kidney Dis,2004,44(2):250-256.
|
| 9 |
Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis [J].N Engl J Med,2008,359(6):584-592.
|
| 10 |
2012 Annual Report of the Dialysis Outcomes and Practice Patterns Study. Hemodialysis Data 1997-2011 [DB/OL]. Ann Arbor, MI:Arbor Research Collaborative for Health,2013 [2014-06-12]. http:/ /www. dopps.org/ annualreport.
|
| 11 |
上海市透析登记报告. 上海地区血液透析患者高血磷的患病率[DB/OL]. 上海: 上海市透析登记网络. 2012 [2014-06-12].http:/ /www.cnrds.org.
|
| 12 |
Locatelli F, Cannata-Andia JB, Drueke TB, et al. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia[J]. Nephrol Dial Transplant,2002,17(5):723-731.
|
| 13 |
Zhang Q, Qiu J, Li H, et al. Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD [J]. J Am Soc Nephrol,2011,22(4):664-672.
|
| 14 |
Kanatani M, Sugimoto T, Kano J, et al. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity [J]. J Cell Physiol,2003,196(1):180-189.
|
| 15 |
Batista DG, Neves KR, Graciolli FG, et al. The bone histology spectrum in experimental renal failure: adverse effects of phosphate and parathyroid hormone disturbances [J]. Calcif Tissue Int,2010,87(1):60-67.
|
| 16 |
Jono S, McKee MD, Murry CE, et al. Phosphate regulation of vascular smooth muscle cell calcification [J]. Circ Res, 2000, 87(7):10-17.
|
| 17 |
Yan P, Li H, Hao C, et al. 2D-speckle tracking echocardiography contributes to early identification of impaired left ventricular myocardial function in patients with chronic kidney disease [J].Nephron Clin Pract,2011,118(3):232-240.
|
| 18 |
Danese MD, Belozeroff V, Smirnakis K, et al. Consistent control of mineral and bone disorder in incident hemodialysis patients [J].Clin J Am Soc Nephrol,2008,3(5):1423-1429.
|
| 19 |
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis,evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [J]. Kidney Int, 2009,76(Suppl 113): S1-S130.
|
| 20 |
Kopple JD. The National Kidney Foundation K/DOQI clinical practice guidelines for dietary protein intake for chronic dialysis patients [J]. Am J Kidney Dis,2001,38(4 Suppl 1): S68-S73.
|
| 21 |
Shinaberger CS, Greenland S, Kopple JD, et al. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease [J] ? Am J Clin Nutr,2008,88(6):1511-1518.
|
| 22 |
Schucker JJ, Ward KE. Hyperphosphatemia and phosphate binders[J]. Am J Health Syst Pharm,2005,62(22):2355-2361.
|
| 23 |
Kovesdy CP. How KDIGO will ( or will not) influence the management of hyperphosphatemia [J]. Semin Dial,2011,24(1):35-36.
|
| 24 |
Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure[J]. N Engl J Med,2010,362(14):1312-1324.
|
| 25 |
Kuhlmann MK. Management of hyperphosphatemia [J]. Hemodial Int,2006,10(4):338-345.
|
| 26 |
Lindsay RM, Alhejaili F, Nesrallah G, et al. Calcium and phosphate balance with quotidian hemodialysis [J]. Am J Kidney Dis,2003,42(1 Suppl):24-29.
|
| 27 |
Wang M, Li H, Liao H, et al. Phosphate removal model: an observational study of low-flux dialyzers in conventional hemodialysis therapy [J]. Hemodial Int,2012,16(3):363-376.
|
| 28 |
Wang M, You L, Li H, et al. Association of circulating fibroblast growth factor-23 with renal phosphate excretion among hemodialysis patients with residual renal function [J]. Clin J Am Soc Nephrol,2013,8(1):116-125.
|
| 29 |
Li H, Long Q, Shao C, et al. Effect of short-term low-protein diet supplemented with keto acids on hyperphosphatemia in maintenance hemodialysis patients [J]. Blood Purif,2011,31(1-3):33-40.
|
| 30 |
Chen J. Nutrition, phosphorus, and keto-analogues in hemodialysis patients: a Chinese perspective [J]. J Ren Nutr, 2013, 23(3):214-217.
|